EP2508187A1 — Triflusal powder containing cyclodextrin as a stabilizing agent
Assigned to Simbec Iberica SL · Expires 2012-10-10 · 14y expired
What this patent protects
The present invention proposes a stable triflusal compound powder for oral administration solid pharmaceutical forms, which contains, as a stabilizing excipient, at least one cyclodextrin selected from: β-cyclodextrin, α-cyclodextrin, dimethyl-β-cyclodextrin, γ-cyclodextrin, 2-hy…
USPTO Abstract
The present invention proposes a stable triflusal compound powder for oral administration solid pharmaceutical forms, which contains, as a stabilizing excipient, at least one cyclodextrin selected from: β-cyclodextrin, α-cyclodextrin, dimethyl-β-cyclodextrin, γ-cyclodextrin, 2-hydroxyethylcyclodextrin, and mixtures thereof. The mentioned triflusal compound powder is used for producing granules, tablets or sachets. The mentioned triflusal compound powder is prepared by dry preparation.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.